Myotonic dystrophies: An update on molecular pathogenesis;Myotone dystrophien - Aktueller stand der molekularen pathogenese

Aktuelle Neurologie

Volumn 32, Issue 6, 2005, Pages 324-330

  Schoser, B G H ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE CHANNEL;

CHROMOSOME 19Q; CHROMOSOME 3Q; CLINICAL FEATURE; DIABETES MELLITUS; GENE MUTATION; HUMAN; MYOTONIC DYSTROPHY; PATHOGENESIS; REVIEW;

EID: 23844509819     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-834724     Document Type: Review

References (60)

1. Steinert H. Myopathologische Beiträge 1. Über das klinische und anatomische Bild des Muskelschwunds der Myotoniker. Dtsch Z Nervenheilkd 1909; 37: 58-104
2. Batten FE, Gibb HP. Myotonia atrophica. Brain 1909; 32: 187-205
3. Curschmann H. Über familiäre atrophische Myotonie. Dtsch Z Nervenheilkd 1912; 45: 161-202
4. Curschmann H. Myotonische Dystrophie (atrophische Myotonie). In: Bumke, Forster (Hrsg): Handbuch der Neurologie. Berlin: Springer Verlag, 1936: 465-485
5. Harper PS. Myotonic Dystrophy, Third Edition. London: W. B. Sauders, 2001
6. Brook JD, McCurrach ME, Harley HG et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992; 68: 799-808
7. Mahadevan M, Tsilfidis C, Sabourin L et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science 1992; 255: 1253-1255
8. Ricker K, Koch MC, Lehmann-Horn F et al. Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 1994; 44: 1448-1452
9. Ricker K, Koch MC, Lehmann-Horn F et al. Proximal myotonic myopathy. Clinical features of a multisystem disorder similar to myotonic dystrophy. Arch Neurol 1995; 52: 25-31
10. rd RT. Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol 1994; 35: 269-272
11. Ranum LP, Rasmussen PF, Benzow KA et al. Genetic mapping of a second myotonic dystrophy locus. Nat Genet 1998; 19: 196-198
12. Liquori CL, Ricker K, Moseley ML et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001; 293: 864-867
13. Ranum LPW, Day JW. Myotonic dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet 2004; 74: 793-804
14. Day JW, Ranum LP. RNA pathogenesis of the myotonic dystrophies. Neuromuscul Disord 2005; 15: 5-16
15. Day JW, Ricker K, Jacobson JF et al. Myotonic dystrophy type 2. Neurology 2003; 60: 657-664
16. Bachinski LL, Udd B, Meola G et al. Confirmation of DM2 (CCTG)n expansion mutation in PROMM/PDM patients of different European origins: a single shared haplotype indicates ancestral founder effects. Am J Hum Genet 2003; 73: 835-848
17. Liquori CL, Ikeda Y, Weatherspoon M et al. Myotonic Dystrophy Type 2: Human founder haplotype and evolutionary conservation of the re-peat tract. Am J Hum Genet 2003; 73: 849-862
18. Ber I Le, Martinez M, Campion D et al. A non-DM1, non-DM2 multisystem myotonic disorder with frontotemporal dementia: phenotype and suggestive mapping of the DM2 locus to chromosome 15q21-24. Brain 2004; 127: 1979-1992
19. Fardaei M, Rogers MT, Thorpe HM et al. Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. Hum Mol Genet 2002; 11: 805-814
20. Ho TH, Charlet-B N, Poulos MG et al. Muscleblind proteins regulate alternative splicing. EMBO 2004; 23: 3103-3112
21. Mankodi A, Urbinati CR, Yuan QP et al. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet 2001; 10: 2165-2170
22. Mankodi A, Teng-Umnuay P, Krym M et al. Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol 2003; 54: 760-768
23. Miller JW, Urbinatii CR, Teng-Umnuay P et al. Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophy. EMBO 2000; 17: 44339-44448
24. Wöhrle D, Steinbach P. Myotone Dystrophie. Pathologischer "gain of function" auf RNA-Ebene. Medgen 2003; 15: 80-85
25. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Ann Rev Biochem 2003; 72: 291-336
26. Herbert A. The four Rs of RNA-directed evolution. Nat Genet 2004; 36: 19-25
27. Ebralidze A, Wang Y, Petkova V et al. RNA leaching of transcription factors disrupts transcription in myotonic dystrophy. Science 2003; 303: 383-387
28. Ladd AN, Charlet N, Cooper TA. The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing. Mol Cell Biol 2001; 21: 1285-1296
29. Timchenko NA, Cai ZJ, Welm AL et al. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem 2001; 276: 7820-7826
30. Schoser BGH, Schneider-Gold C, Reilich P et al. Muscle pathology in 57 patients with myotonic dystrophy type 2. Muscle&Nerve 2004; 29: 275-281
31. Buj-Bello A, Furling D, Tronchere H et al. Muscle-specific alternative splicing of myotubularin-related 1 gene is impaired in DM1 muscle cells. Hum Mol Genet 2002; 11: 2297-2307
32. Kanadia RN, Johnstone KA, Mankodi A et al. A muscleblind knockout model for myotonic dystrophy. Science 2003; 302: 1978-1980
33. Savkur RS, Philips AV, Cooper TA et al. Insulin receptor splicing alteration in myotonic dystrophy type 2. Am J Hum Genet 2004; 74: 1309-1313
34. Timchenko NA, Patel R, Iakova P et al. Overexpression of CUG triplet repeat binding protein, CUGBP1 in mice inhibits myogenesis. J Biol Chem 2004; 279: 13129-13139
35. Logigian EL, Moxley RT, Blood CL et al. Leukocyte CTG repeat length correlates with severity of myotonia in myotonic dystrophy type 1. Neurology 2004; 62: 1081-1089
36. Charlet BN, Savkur RS, Singh G et al. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 2002; 10: 45-53
37. Mankodi A, Takahashi MP, Jiang H et al. Expanded CUG Repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 2002; 10: 35-44
38. Hund E, Jansen O, Koch MC et al. Proximal myotonic myopathy with MRI white matter abnormalities of the brain. Neurology 1997; 48: 33-37
39. Kassubek J, Juengling FD, Hoffmann S et al. Quantification of brain atrophy in patients with myotonic dystrophy and proximal myotonic myopathy: a controlled 3-dimensional magnetic resonance imaging study. Neurosci Lett 2003; 348: 73-76
40. Kornblum C, Reul J, Kress W et al. Cranial magnetic resonance imaging in genetically proven myotonic dystrophy type 1 and 2. J Neurol 2004; 251: 710-714
41. Meola G, Sansone V, Perani D et al. Reduced cerebral blood flow and impaired visual-spatial function in proximal myotonic myopathy. Neurology 1999; 53: 1042-1050
42. Meola G, Sansone V, Perani D et al. Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM1) and in proximal myotonic myopathy (PROMM/DM2). Neuromuscl Disord 2003; 13: 813-821
43. Schneider C, Reiners K, Toyka KV. Myotone Dystrophie (DM/Curschmann- Steinert-Erkrankung) und proximale myotone Myopathy (PROMM/Ricker-Syndrom). Myotone Muskelerkrankungen mit multisystemischen Manifestationen. Nervenarzt 2001; 72: 618-624
44. Sergeant N, Sablonniere B, Schraen-Maschke S et al. Dysregulation of human brain microtuble-associated tau mRNA maturation in myotonic dystrophy type 1. Hum Mol Gen 2001; 10: 2143-2155
45. th ENMC workshop: DM2/PROMM and other myotonic dystrophies. 3rd Workshop, 14-16 February 2003, Naarden, The Netherlands. Neuromuscl Disord 2003; 13: 589-596
46. Sarkar PS, Appukuttan B, Han J et al. Heterozygous loss of Six5 in mice is sufficient to cause ocular cataracts. Nat Genet 2000; 25: 110-114
47. Sato S, Nakamura M, Cho DH et al. Identification of transcriptional targets for Six5: implication for the pathogenesis of myotonic dystrophy type 1. Hum Mol Genet 2002; 11: 1045-1058
48. Antonini G, Giubilei F, Mammarella A. Natural history of cardiac involvement in myotonic dystrophy: correlation with CTG repeats. Neurology 2000; 55: 1207-1209
49. Bhakta D, Lowe MR, Groh WJ. Prevalence of structural cardiac abnormalities in patients with myotonic dystrophy type 1. Am Heart J 2004; 147: 224-227
50. Pelargonio G, Dello Russo A, Sanna T et al. Myotonic dystrophy and the heart. Heart 2002; 88: 665-670
51. Schoser BGH, Ricker K, Schneider-Gold C et al. Sudden death in myotonic dystrophy type 2. Neurology 2004; 63: 966-967
52. Schneider-Gold C, Beer M, Kostler H et al. Cardiac and skeletal muscle involvement in myotonic dystrophy type 2 (DM2): a quantitative 31P-MRS and MRI study. Muscle Nerve 2004; 30: 636-644
53. Philips AV, Timchenko LT, Cooper TA. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 1998; 280: 737-741
54. Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001; 29: 40-47
55. Sarkar PS, Paul S, Han J, Reddy S. Six5 is required for spermatogenic cell survival and spermiogenesis. Hum Mol Genet 2004; 13: 1421-1431
56. George A, Schneider-Gold C, Zier S et al. Musculoskeletal pain in patients with myotonic dystrophy type 2. Arch Neurol 2004; 61: 1938-1942
57. rd RT. Myotonic dystrophy type 2 and related myotonic disorders. J Neurol 2004; 251: 1173-1182
58. Jakubiczka S, Vielhaber S, Kress W et al. A strategy for reliable diagnosis of PROMM/DM2. Neurogenetics 2004; 5: 55-59
59. Schoser BGH, Kress W, Walter MC et al. Homozygosity for CCTG mutation in myotonic dystrophy type 2. Brain 2004; 127: 1868-1877
60. Saalinen R, Vihola A, Bachinski LL et al. New methods for molecular diagnosis and demonstration of the (CCTG)n mutation in myotonic dystrophy type 2 (DM2). Neuromuscul Disord 2004; 14: 274-283